Rigel Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

REVENUES - Disaggregated (Details) - USD ($) $ in Thousands	3 Months Ended							12 Months Ended
REVENUES - Disaggregated (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disaggregation of Revenue [Line Items]
Total revenues	$ 15,400	$ 20,857	$ 10,407	$ 12,624	$ 37,857	$ 4,865	$ 1,787	$ 59,288	$ 44,509	$ 4,484
Gross product sales
Disaggregation of Revenue [Line Items]
Total revenues								53,082	16,953
Discounts and allowances
Disaggregation of Revenue [Line Items]
Total revenues								(9,310)	(3,006)
Product sales, net
Disaggregation of Revenue [Line Items]
Total revenues								43,772	13,947
License revenues
Disaggregation of Revenue [Line Items]
Total revenues								8,696	30,562	250
Development milestones
Disaggregation of Revenue [Line Items]
Total revenues								5,500		4,234
Research and development services and others
Disaggregation of Revenue [Line Items]
Total revenues								1,320
Contract revenues from collaborations
Disaggregation of Revenue [Line Items]
Total revenues								$ 15,516	$ 30,562	4,484
TAVALISSE
Disaggregation of Revenue [Line Items]
Total revenues										$ 0